Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy-Reference-Cited by-同舟云学术

Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy

Published:2022-12-01 Issue:6 Volume:11 Page:617-620
ISSN:2156-5333
Container-title:Journal of Adolescent and Young Adult Oncology
language:en
Short-container-title:Journal of Adolescent and Young Adult Oncology

Author:

Ashraf Sarah¹,Wolfson Julie²,Vachhani Pankit³,Rangaraju Sravanti³,Bachiashvili Kimo³,Bhatia Ravi³,Jamy Omer³^ORCID

Affiliation:

1. The Aga Khan University-Medical College, Karachi, Pakistan.

2. Division of Pediatric Hematology-Oncology, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA.

3. Division of Hematology Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Publisher

Mary Ann Liebert Inc

Subject

Oncology,Pediatrics, Perinatology and Child Health

Link

https://www.liebertpub.com/doi/pdf/10.1089/jayao.2021.0200

Reference19 articles.

1. Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

2. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL- positive acute lymphoblastic leukemia

3. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

4. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations;Expert Review of Hematology;2023-04-20

2. Antineoplastics/hydrocortisone;Reactions Weekly;2023-02-04